Telix Pharmaceuticals to raise $200m for final stage prostate cancer therapy trials

Melbourne-headquartered nuclear medicine company Telix Pharmaceuticals (ASX: TLX) has completed a $175 million institutional placement to fund final-stage trials of a prostate cancer therapy and the roll-out of its first commercial product Illucix, a prostate cancer imaging product approved by…